Policymakers, Drug Companies Must Prioritize Biomedical Research To Address Antimicrobial Resistance
Fox News: We must fight the deadly superbug threat with every tool we’ve got
Claire Pomeroy, president of the Albert and Mary Lasker Foundation
“…The number of new antimicrobial agents in development has slowed and the antibiotic pipeline is insufficient. Investigators must embrace the importance of this field of research; policymakers must ensure that regulations do not discourage R&D; and pharmaceutical companies must invest in their development. We must prioritize research to develop new drugs; to identify new ways to prevent, diagnose, and treat infection; and to clarify the best ways to use the antimicrobial tools available to us. … [W]e must also explore new ways to combat infection — from behavioral interventions that can decrease spread of disease, to strengthening health care infrastructure so infections are treated quickly before they can extend to others. … We must join our voices to make this public health threat a policy and research priority and impress upon our elected representatives and policymakers at home and abroad the importance of funding for biomedical research…” (3/17).